Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
In current clinical practice, the GLP-1 receptor agonists with approved indications for the treatment of pediatric obesity are liraglutide and semaglutide
For anyone interested in using Semaglutide as an aid in their weight loss efforts, it should always be done under the care of an experienced Diabetes care or Obesity/Weight management specialists physician familiar with the drugs use and potential side effects so that safety and efficacy are maintained at all times
If pregnant, breastfeeding, or currently taking medication, consult a healthcare professional before use
As of July 2026, Ro has fully exited compounded GLP-1s and sells only FDA-approved branded medication: Wegovy oral pill at $149/month for the first month, rising to $199$299/month at higher ongoing doses
US$ 26.45
US$ 24.28
US$ 25.16
